King Pharmaceuticals wins preliminary injunction against CorePharma over generic version of Skelaxin®

Client(s) King Pharmaceuticals, Inc.

Jones Day successfully halted sales of a generic version of Skelaxin®, King Pharmaceuticals, Inc.'s best-selling product. Skelaxin® (metaxalone) is a muscle relaxant used to treat acute, painful musculoskeletal conditions. In 2009, U.S. sales of Skelaxin® exceeded $400 million. The U.S. District Court for the District of New Jersey issued a preliminary injunction barring CorePharma, LLC from engaging in the use, offer to sell, or sale of its generic metaxalone product pending a resolution on the merits of the action. King and CorePharma were parties to an agreement that granted CorePharma rights to market an authorized generic version of Skelaxin® under certain limited circumstances. The Court found that CorePharma was in breach for acting outside of its authorization under the agreement.

King Pharmaceuticals, Inc., et al. v. CorePharma, LLC, Civil Action No. 3-10-cv-01878 (D.N.J.)